File: According to the WHO, 34 vaccine candidates worldwide are currently in the various phases of being tested on humans, while a further 142 are in pre-clinical evaluation.
WASHINGTON - Moderna Inc said on Monday it has started a US government-backed late-stage trial to assess its COVID-19 vaccine candidate in about 30,000 adults who do not have the respiratory illness caused by the new coronavirus.
Cambridge, Massachusetts-based Moderna's shares were up 11% at $81.31 before the bell.
The trial, named COVE, is the first to be implemented under the US government's Operation Warp Speed that aims to accelerate the development, manufacturing and distribution of therapeutics and vaccines for COVID-19.
The federal government is supporting Moderna's vaccine project with nearly a billion dollars and has chosen it as one of the first to enter large-scale human trials.
The main goal of the study will be the prevention of the symptomatic COVID-19 disease, the company said.